|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Motzer RJ, Bander NH and Nanus DM:
Renal-Cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fontana F, Raimondi M, Marzagalli M, Di
Domizio A and Limonta P: The emerging role of paraptosis in tumor
cell biology: Perspectives for cancer prevention and therapy with
natural compounds. Biochim Biophys Acta Rev Cancer.
1873:1883382020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cho CW, Kim YC, Kang JH, Rhee YK, Choi SY,
Kim KT, Lee YC and Hong HD: Characteristic study on the chemical
components of Korean curved ginseng products. J Ginseng Res.
37:349–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang XD, Yang YY, Ouyang DS and Yang GP: A
review of biotransformation and pharmacology of ginsenoside
compound K. Fitoterapia. 100:208–220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gan XT and Karmazyn M: Cardioprotection by
ginseng: Experimental and clinical evidence and underlying
mechanisms. Can J Physiol Pharmacol. 96:859–868. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oh J and Kim JS: Compound K derived from
ginseng: Neuroprotection and cognitive improvement. Food Funct.
7:4506–4515. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hasegawa H, Sung JH, Matsumiya S and
Uchiyama M: Main ginseng saponin metabolites formed by intestinal
bacteria. Planta Med. 62:453–457. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim H, Roh HS, Kim JE, Park SD, Park WH
and Moon JY: Compound K attenuates stromal cell-derived growth
factor 1 (SDF-1)-induced migration of C6 glioma cells. Nutr Res
Pract. 10:259–264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee S, Kwon MC, Jang JP, Sohng JK and Jung
HJ: The ginsenoside metabolite compound K inhibits growth,
migration and stemness of glioblastoma cells. Int J Oncol.
51:414–424. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shin DH, Leem DG, Shin JS, Kim JI, Kim KT,
Choi SY, Lee MH, Choi JH and Lee KT: Compound K induced apoptosis
via endoplasmic reticulum Ca2+ release through ryanodine
receptor in human lung cancer cells. J Ginseng Res. 42:165–174.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen HF, Wu LX, Li XF, Zhu YC, Wang WX, Xu
CW, Huang ZZ and Du KQ: Ginsenoside compound K inhibits growth of
lung cancer cells via HIF-1α-mediated glucose metabolism. Cell Mol
Biol (Noisy-le-grand). 65:48–52. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Y, Xu Y, Zhu Y and Li X: Anti-Cancer
effects of ginsenoside compound k on pediatric acute myeloid
leukemia cells. Cancer Cell Int. 13:242013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Law CK, Kwok HH, Poon PY, Lau CC, Jiang
ZH, Tai WC, Hsiao WW, Mak NK, Yue PY and Wong RN: Ginsenoside
compound K induces apoptosis in nasopharyngeal carcinoma cells via
activation of apoptosis-inducing factor. Chin Med. 9:112014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang CZ, Du GJ, Zhang Z, Wen XD, Calway T,
Zhen Z, Musch MW, Bissonnette M, Chang EB and Yuan CS: Ginsenoside
compound K, not Rb1, possesses potential chemopreventive activities
in human colorectal cancer. Int J Oncol. 40:1970–1976.
2012.PubMed/NCBI
|
|
16
|
Yu R, Yu BX, Chen JF, Lv XY, Yan ZJ, Cheng
Y and Ma Q: Anti-Tumor effects of atractylenolide I on bladder
cancer cells. J Exp Clin Cancer Res. 35:402016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yates AD, Achuthan P, Akanni W, Allen J,
Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Azov AG, Bennett
R, et al: Ensemble 2020. Nucleic Acids Res. 48:D682–D688.
2020.PubMed/NCBI
|
|
19
|
Martinotti S and Ranzato E: Scratch wound
healing assay. Methods Mol Biol. 2109:225–229. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
American Association for Laboratory Animal
Science, . AALAS position statement on the humane care and use of
laboratory animals. Com Med. 4:4132007.
|
|
21
|
Brodaczewska KK, Szczylik C, Fiedorowicz
M, Porta C and Czarnecka AM: Choosing the right cell line for renal
cell cancer research. Mol Cancer. 15:832016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oh JM, Kim E and Chun S: Ginsenoside
compound K induces ros-mediated apoptosis and autophagic inhibition
in human neuroblastoma cells in vitro and in vivo. Int J Mol Sci.
20:42792019. View Article : Google Scholar
|
|
23
|
Kim AD, Kang KA, Kim HS, Kim DH, Choi YH,
Lee SJ, Kim HS and Hyun JW: A ginseng metabolite, compound K,
induces autophagy and apoptosis via generation of reactive oxygen
species and activation of JNK in human colon cancer cells. Cell
Death Dis. 4:e7502013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qi LW, Wang CZ, Du GJ, Zhang ZY, Calway T
and Yuan CS: Metabolism of ginseng and its interactions with drugs.
Curr Drug Metab. 12:818–822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paek IB, Moon Y, Kim J, Ji HY, Kim SA,
Sohn DH, Kim JB and Lee HS: Pharmacokinetics of a ginseng saponin
metabolite compound K in rats. Biopharm Drug Dispos. 27:39–45.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang X, Zhang S, Sun Q, Jiao W, Yan Y and
Zhang X: Compound K induces endoplasmic reticulum stress and
apoptosis in human liver cancer cells by regulating STAT3.
Molecules. 19:14822018. View Article : Google Scholar
|
|
27
|
Yao H, Wan JY, Zeng J, Huang WH,
Sava-Segal C, Li L, Niu X, Wang Q, Wang CZ and Yuan CS: Effects of
compound K, an enteric microbiome metabolite of ginseng, in the
treatment of inflammation associated colon cancer. Oncol Lett.
15:8339–8348. 2018.PubMed/NCBI
|
|
28
|
Zhang K and Li Y: Effects of ginsenoside
compound K combined with cisplatin on the proliferation, apoptosis
and epithelial mesenchymal transition in MCF-7 cells of human
breast cancer. Pharm Biol. 54:561–568. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Piva F, Giulietti M, Santoni M, Occhipinti
G, Scarpelli M, Lopez-Beltran A, Cheng L, Principato G and
Montironi R: Epithelial to mesenchymal transition in renal cell
carcinoma: Implications for cancer therapy. Mol Diagn Ther.
20:111–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boice A and Bouchier-Hayes L: Targeting
apoptotic caspases in cancer. Biochim Biophys Acta Mol Cell Res.
1867:1186882020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vallejo MJ, Salazar L and Grijalva M:
Oxidative stress modulation and ROS-mediated toxicity in cancer: A
review on in vitro models for plant-derived compounds. Oxid Med
Cell Longev. 2017:45860682017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huarte M: The emerging role of lncRNAs in
cancer. Nat Med. 21:1253–1261. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ye XT, Huang H, Huang WP and Hu WL: LncRNA
THOR promotes human renal cell carcinoma cell growth. Biochem
Biophys Res Commun. 501:661–667. 2018. View Article : Google Scholar : PubMed/NCBI
|
